Pharmacotherapy for parents with attention-deficit hyperactivity disorder (ADHD): impact on maternal ADHD and parenting.

abstract：BACKGROUND:A recent large database analysis raised concerns of potential acute kidney injury (AKI) risk associated with antipsychotics. However, whether individual atypical and typical antipsychotics are associated with differential AKI risks has not been investigated. OBJECTIVE:The current study compared the risks of...

journal_title：CNS drugs

authors： Jiang Y,McCombs JS,Park SH

更新日期：2017-04-01 00:00:00

abstract：:The almost ubiquitous sleep disturbances in patients with depression commonly, but not always, subside with the remission of depression. Evidence linking insomnia with the risk of relapses in recurrent depression, as well as suicide, makes optimization of the treatment of insomnia associated with depression a priority...

journal_title：CNS drugs

authors： Jindal RD

更新日期：2009-01-01 00:00:00

abstract：:Teriflunomide is a once-daily oral agent that has been licensed in the EU since August 2013 for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS). More recently (September 2014), the EU summary of product characteristics (SmPC) was updated to include data from patients with a first cli...

journal_title：CNS drugs

authors： Chan A,de Seze J,Comabella M

更新日期：2016-01-01 00:00:00

abstract：:There is escalating interest in cell-based therapies to restore lost dopamine inputs in Parkinson's disease. This is based upon the rationale that implanting dopamine progenitors into the striatum can potentially improve dopamine-responsive motor symptoms. A rich body of data describing clinical trials of previous cel...

journal_title：CNS drugs

authors： Henchcliffe C,Sarva H

更新日期：2020-06-01 00:00:00

abstract：SYNOPSIS:Mirtazapine is a tetracyclic antidepressant with a novel mechanism of action; it increases noradrenergic and serotonergic neurotransmission via blockade of central α2-adrenergic auto- and heteroreceptors. The increased release of serotonin (5-hydroxytryptamine; 5-HT) stimulates serotonin 5-HT1 receptors becaus...

journal_title：CNS drugs

authors： Davis R,Wilde MI

更新日期：1996-05-01 00:00:00

abstract：:Seizures are a relatively common occurrence in patients with HIV infection. They may be a result of HIV infection of the CNS or a manifestation of an opportunistic infection. Because seizures are likely to recur in patients infected with HIV and because they are a poor prognostic indicator, it is generally recommended...

journal_title：CNS drugs

authors： Romanelli F,Ryan M

更新日期：2002-01-01 00:00:00

abstract：:Oxcarbazepine (Trileptal, Timox) is structurally related to carbamazepine and has anticonvulsant activity. Studies suggest that the anticonvulsant activity of oxcarbazepine is mediated via the blocking of neuronal ion channels. In patients aged <18 years, the efficacy of oxcarbazepine monotherapy was similar to that o...

journal_title：CNS drugs

authors： Bang LM,Goa KL

更新日期：2004-01-01 00:00:00

abstract：:Friedreich ataxia (FA) is a progressive genetic neurological disorder associated with degeneration of the dorsal columns, spinocerebellar tracts and other regions of the nervous system. The disorder results from mutations in the gene referred to as FXN. Almost all mutations are expansions of an intronic GAA repeat in ...

journal_title：CNS drugs

authors： Tsou AY,Friedman LS,Wilson RB,Lynch DR

更新日期：2009-01-01 00:00:00

abstract：:Lisdexamfetamine dimesylate (lisdexamfetamine) is a long-acting amfetamine prodrug with a convenient once-daily oral regimen that offers the potential for improved adherence and reduced abuse compared with short-acting preparations of amfetamines. Lisdexamfetamine (as Elvanse Adult(®); Tyvense Adult™) has been approve...

journal_title：CNS drugs

authors： Frampton JE

更新日期：2016-04-01 00:00:00

abstract：:Parkinson's disease is a disabling hypokinetic neurological movement disorder in which the aetiology is unknown in the majority of cases. Current pharmacological treatments, though effective at restoring movement, are only symptomatic and do nothing to slow disease progression. Electrophysiological, epidemiological an...

journal_title：CNS drugs

authors： Swart T,Hurley MJ

更新日期：2016-12-01 00:00:00

abstract：:The kynurenine pathway constitutes the main route of tryptophan degradation and generates the production of several neuroactive compounds; quinolinic acid is an excitotoxic NMDA receptor agonist, 3-hydroxykynurenine is a free-radical generator and kynurenic acid (KYNA) is an antagonist at glutamate and nicotinic recep...

journal_title：CNS drugs

authors： Erhardt S,Olsson SK,Engberg G

更新日期：2009-01-01 00:00:00

abstract：:Premature mortality due to cardiovascular disease in those with schizophrenia is the largest lifespan disparity in the US and is growing; adults in the US with schizophrenia die, on average, 28 years earlier than those in the general population. The rate of smoking prevalence among individuals with schizophrenia is es...

journal_title：CNS drugs

authors： Cather C,Pachas GN,Cieslak KM,Evins AE

更新日期：2017-06-01 00:00:00

abstract：:It is difficult to determine the relative efficacy of atypical antipsychotics for the treatment of schizophrenia, based on the available literature. The purpose of this article is to review and compare the efficacy of two atypical antipsychotics: olanzapine and ziprasidone.This review focused on randomised trials in w...

journal_title：CNS drugs

authors： Matza LS,Baker TM,Revicki DA

更新日期：2005-01-01 00:00:00

abstract：BACKGROUND:Responses to atomoxetine vary for individual patients with attention-deficit/hyperactivity disorder (ADHD). However, we do not know whether any factors can be used to reliably predict how individuals with ADHD will respond to treatment. OBJECTIVE:Our objective was to evaluate background variables that facil...

journal_title：CNS drugs

authors： Bushe C,Sobanski E,Coghill D,Berggren L,De Bruyckere K,Leppämäki S

更新日期：2016-04-01 00:00:00

abstract：:Bulimia nervosa is an eating disorder characterised by recurrent episodes of binge eating and associated efforts to purge the ingested calories through self-induced vomiting, laxative or diuretic abuse, fasting or intensive exercise. The aetiopathogenesis and pathophysiology of the disorder are currently unclear. Biol...

journal_title：CNS drugs

authors： Brambilla F

更新日期：2001-01-01 00:00:00

abstract：:The development of an intervention to slow or halt disease progression remains the greatest unmet therapeutic need in Parkinson's disease. Given the number of failures of various novel interventions in disease-modifying clinical trials in combination with the ever-increasing costs and lengthy processes for drug develo...

journal_title：CNS drugs

authors： Athauda D,Foltynie T

更新日期：2018-08-01 00:00:00

abstract：:All antipsychotics, including the atypical antipsychotics (AAPs), may cause tardive dyskinesia (TD), a potentially irreversible movement disorder, the pathophysiology of which is currently unknown. The prevention and treatment of TD remain major challenges for clinicians. We conducted a PubMed search to review the pre...

journal_title：CNS drugs

authors： Stegmayer K,Walther S,van Harten P

更新日期：2018-02-01 00:00:00

abstract：:Secondary progressive multiple sclerosis (SPMS) is diagnosed retrospectively and involves a clinical course characterized by a progressive accumulation of neurological disability, independent of relapses, following an initial relapsing-remitting (RR) phase. Our incomplete understanding of the pathological mechanisms u...

journal_title：CNS drugs

authors： Plantone D,De Angelis F,Doshi A,Chataway J

更新日期：2016-06-01 00:00:00

abstract：:A number of news items and case reports describing complex behaviours (e.g. sleep driving, sleep cooking, sleep eating, sleep conversations, sleep sex) associated with the use of hypnosedative medications have recently received considerable attention. Regulatory agencies examining these reports have subsequently issue...

journal_title：CNS drugs

authors： Dolder CR,Nelson MH

更新日期：2008-01-01 00:00:00

abstract：:Female hypoactive sexual desire disorder (HSDD) may occur in up to one-third of adult women in the US. The essential feature of female HSDD is a deficiency or absence of sexual fantasies and desire for sexual activity that causes marked distress or interpersonal difficulty. The evaluation of female HSDD generally requ...

journal_title：CNS drugs

authors： Warnock JJ

更新日期：2002-01-01 00:00:00

abstract：:Symptoms of anxiety and depression often appear together in patients, either as 2 discrete disorders, such as major depressive disorder and panic disorder, or as a combination of symptoms not meeting criteria for specific disorders. The social, economic, occupational and medical costs of such comorbid anxiety and depr...

journal_title：CNS drugs

authors： Bakish D,Habib R,Hooper CL

更新日期：1998-04-01 00:00:00

abstract：INTRODUCTION:The use of methylphenidate for the treatment of attention deficit-hyperactivity disorder (ADHD) has increased dramatically in the past decade in some countries in Europe and North America. In response to a public debate in Israel, several Knesset members introduced a legislative initiative that aims to lim...

journal_title：CNS drugs

authors： Fogelman Y,Vinker S,Guy N,Kahan E

更新日期：2003-01-01 00:00:00

abstract：UNLABELLED:Tianeptine is an antidepressant agent with a novel neurochemical profile. It increases serotonin (5-hydroxytryptamine; 5-HT) uptake in the brain (in contrast with most antidepressant agents) and reduces stress-induced atrophy of neuronal dendrites. Like the selective serotonin reuptake inhibitors (SSRIs) and...

journal_title：CNS drugs

authors： Wagstaff AJ,Ormrod D,Spencer CM

更新日期：2001-01-01 00:00:00

abstract：:Insomnia, an inability to initiate or maintain sleep, affects approximately one-third of the American population. Conventional benzodiazepines, such as triazolam and midazolam, were the treatment of choice for short-term insomnia for many years but are associated with adverse effects such as rebound insomnia, withdraw...

journal_title：CNS drugs

authors： Hesse LM,von Moltke LL,Greenblatt DJ

更新日期：2003-01-01 00:00:00

abstract：BACKGROUND:Walking impairment is a hallmark of multiple sclerosis (MS). It affects > 90% of individuals over time, reducing independence and negatively impacting health-related quality of life, productivity, and daily activities. Walking impairment is consistently reported as one of the most distressing impairments by ...

journal_title：CNS drugs

authors： Hobart J,Ziemssen T,Feys P,Linnebank M,Goodman AD,Farrell R,Hupperts R,Blight AR,Englishby V,McNeill M,Chang I,Lima G,Elkins J,ENHANCE study investigators.

更新日期：2019-01-01 00:00:00

abstract：BACKGROUND:Diroximel fumarate (DRF) is a novel oral fumarate approved in the USA for relapsing forms of multiple sclerosis. DRF is converted to monomethyl fumarate, the pharmacologically active metabolite of dimethyl fumarate (DMF). DRF 462 mg and DMF 240 mg produce bioequivalent exposure of monomethyl fumarate and are...

journal_title：CNS drugs

authors： Naismith RT,Wundes A,Ziemssen T,Jasinska E,Freedman MS,Lembo AJ,Selmaj K,Bidollari I,Chen H,Hanna J,Leigh-Pemberton R,Lopez-Bresnahan M,Lyons J,Miller C,Rezendes D,Wolinsky JS,EVOLVE-MS-2 Study Group.

更新日期：2020-02-01 00:00:00

abstract：OBJECTIVES:Atomoxetine is commonly used to treat attention-deficit hyperactivity disorder (ADHD) in children with a broad range of cognitive abilities. We examined the association between level of cognitive functioning as determined by IQ and clinical response during treatment with atomoxetine. METHODS:The records of ...

journal_title：CNS drugs

authors： Mazzone L,Reale L,Mannino V,Cocuzza M,Vitiello B

更新日期：2011-06-01 00:00:00

abstract：:Satisfactory management of Parkinson's disease is a challenge that requires a tailored approach for each individual. In the advanced phase of the disease, patients may experience motor complications despite optimized pharmacological therapy. Apomorphine, a short-acting D1- and D2-like receptor agonist, is the only dru...

journal_title：CNS drugs

authors： Carbone F,Djamshidian A,Seppi K,Poewe W

更新日期：2019-09-01 00:00:00

abstract：:A wide range of support is available to help smokers to quit and to aid attempts at harm reduction, including three first-line smoking cessation medications: nicotine replacement therapy, varenicline and bupropion. Despite the efficacy of these, there is a continual need to diversify the range of medications so that t...

journal_title：CNS drugs

authors： Beard E,Shahab L,Cummings DM,Michie S,West R

更新日期：2016-10-01 00:00:00

abstract：BACKGROUND:Dravet syndrome (DS) is one of the most severe forms of drug-resistant epilepsy and available interventions fail to control seizures in most patients. Cannabidiol (CBD) is the first in a new class of antiepileptic drugs with a distinctive chemical structure and mechanism of action. OBJECTIVE:The aim of this...

journal_title：CNS drugs

authors： Lattanzi S,Brigo F,Trinka E,Zaccara G,Striano P,Del Giovane C,Silvestrini M

更新日期：2020-03-01 00:00:00